91188-00-0

91188-00-0 structure

Name: Merafloxacin
Chemical Name: 1-ethyl-7-[3-(ethylamino)methyl]-1-pyrrolidinyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
CAS Number: 91188-00-0
Molecular Formula: C₁₉H₂₃F₂N₃O₃
Molecular Weight: 379.40100
Catalog: Signaling Pathways Anti-infection SARS-CoV
Create Date: 2018-04-19 18:21:38
Modify Date: 2025-08-25 18:46:37
Merafloxacin (CI-934), a fluoroquinolone antibacterial agent, is a selective programmed -1 ribosomal frameshifting (-1 PRF) inhibitor of beta coronaviruses. Merafloxacin exhibits in vitro activity against gram-positive and gram-negative bacteria[1][2].

Name	1-ethyl-7-[3-(ethylamino)methyl]-1-pyrrolidinyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
Synonyms	1-ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid Merafloxacin 1-Ethyl-7-(3-ethylaminomethyl-pyrrolidin-1-yl)-6,8-difluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid 1-ethyl-7-<3-<(ethylamino)methyl>-1-pyrrolidinyl>-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

Description	Merafloxacin (CI-934), a fluoroquinolone antibacterial agent, is a selective programmed -1 ribosomal frameshifting (-1 PRF) inhibitor of beta coronaviruses. Merafloxacin exhibits in vitro activity against gram-positive and gram-negative bacteria[1][2].
Related Catalog	Research Areas >> Infection Signaling Pathways >> Anti-infection >> SARS-CoV
Target	IC50: 19.6 μM (SARS-CoV-2)[1]
In Vitro	Merafloxacin (5-80 μM) dose-dependently inhibits programmed -1 ribosomal frameshifting (-1 PRF) of SARS-CoV-2, SARS-CoV, hCoVO-C43, and hCoV-HKU1, with IC50s of 19.6 μM, 19.5 μM, 29.7 μM, and 38.6 μM, respectively[1].
References	[1]. Sun Y, et, al. Restriction of SARS-CoV-2 Replication by Targeting Programmed -1 Ribosomal Frameshifting In Vitro. bioRxiv. 2020 Oct 21;2020.10.21.349225. [2]. Mandell W, et, al. In vitro activity of CI-934, a new quinolone, compared with that of other quinolones and other antimicrobial agents. Antimicrob Agents Chemother. 1986 May;29(5):852-7.